Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$9.94
$3.49
$10.30
$579.72M2.311.43 million shs1.66 million shs
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$1.18
+12.4%
$1.98
$0.39
$18.00
$5.59M3.533,866 shs743 shs
Isoray, Inc. stock logo
ISR
Isoray
$0.37
$0.19
$0.45
$54.57M1.48290,697 shs145,000 shs
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$0.07
$0.52
$0.07
$23.40
$352K1.311.41 million shs72,694 shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
0.00%0.00%0.00%0.00%0.00%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
+12.38%+4.42%-44.86%-75.92%-60.67%
Isoray, Inc. stock logo
ISR
Isoray
0.00%0.00%0.00%0.00%0.00%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-7.65%-59.65%-85.44%-93.36%-99.46%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Isoray, Inc. stock logo
ISR
Isoray
N/AN/AN/AN/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.7638 of 5 stars
3.55.00.00.00.60.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/A
Isoray, Inc. stock logo
ISR
Isoray
N/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
3.00
Buy$28.8841,150.00% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$76.86M0.00N/AN/A$0.69 per share0.00
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K69.92N/AN/A($2.43) per share-0.49
Isoray, Inc. stock logo
ISR
Isoray
$10.80M0.00N/AN/A$0.43 per share0.00
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$320K1.10N/AN/A$1.74 per share0.04

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
-$39.84M-$1.02N/AN/AN/A-51.84%-89.48%-33.76%N/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)
Isoray, Inc. stock logo
ISR
Isoray
-$7.27M-$0.07N/AN/AN/A-115.91%-17.12%-16.15%N/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-$12.87M-$28.55N/AN/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)

Latest ARTH, ISR, MOTS, and APEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q4 2023
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/A-$4.13-$4.13-$3.78N/A$0.06 million
2/20/2024Q1 2024
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A-$0.57-$0.57-$0.57N/A$0.05 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Isoray, Inc. stock logo
ISR
Isoray
N/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
1.04
2.35
1.89
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.16
0.04
Isoray, Inc. stock logo
ISR
Isoray
N/A
14.38
13.99
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.46
1.76
1.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
76.01%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Isoray, Inc. stock logo
ISR
Isoray
11.32%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
20.06%

Insider Ownership

CompanyInsider Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
17.30%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Isoray, Inc. stock logo
ISR
Isoray
2.42%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.57%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
20257.97 million47.94 millionNot Optionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
84.74 million4.53 millionNot Optionable
Isoray, Inc. stock logo
ISR
Isoray
N/A142.11 million138.67 millionNot Optionable
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
155.03 million4.95 millionNot Optionable

ARTH, ISR, MOTS, and APEN Headlines

SourceHeadline
Motus GI Holdings IncMotus GI Holdings Inc
morningstar.com - April 16 at 5:43 PM
Why Is Motus GI (MOTS) Stock Down 37% Today?Why Is Motus GI (MOTS) Stock Down 37% Today?
msn.com - April 12 at 8:50 AM
Why Is Motus GI (MOTS) Stock Down 37% Today?Why Is Motus GI (MOTS) Stock Down 37% Today?
investorplace.com - April 12 at 8:32 AM
Motus GI Holdings files to sell 4.4M common shares for holdersMotus GI Holdings files to sell 4.4M common shares for holders
msn.com - March 23 at 3:58 PM
Motus GI Holdings, Inc.: Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMotus GI Holdings, Inc.: Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - March 19 at 7:57 AM
MOTS Stock Earnings: Motus GI Hldgs Misses EPS, Misses Revenue for Q4 2023MOTS Stock Earnings: Motus GI Hldgs Misses EPS, Misses Revenue for Q4 2023
investorplace.com - March 18 at 11:01 PM
Le BPA de Motus GI Holdings a dépassé les attentes de 1,30$, le CA en dessous des prévisionsLe BPA de Motus GI Holdings a dépassé les attentes de 1,30$, le CA en dessous des prévisions
fr.investing.com - March 18 at 9:55 PM
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMotus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
globenewswire.com - March 18 at 4:05 PM
Motus GI Holdings, Inc. (MOTS)Motus GI Holdings, Inc. (MOTS)
finance.yahoo.com - February 29 at 12:41 PM
EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive OfficerEndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer
businesswire.com - February 29 at 7:57 AM
Motus GI secures new patent for endoscopic proceduresMotus GI secures new patent for endoscopic procedures
investing.com - February 23 at 10:53 PM
Motus GI Holdings Inc.Motus GI Holdings Inc.
wsj.com - February 23 at 10:53 PM
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross ProceedsMotus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
finance.yahoo.com - February 22 at 8:41 AM
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross ProceedsMotus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
globenewswire.com - February 22 at 8:00 AM
Why Is Colonoscopy-Focused Motus GI Stock Trading Higher Today?Why Is Colonoscopy-Focused Motus GI Stock Trading Higher Today?
msn.com - February 21 at 6:01 PM
Crude Oil Moves Higher; Exelon Earnings Top EstimatesCrude Oil Moves Higher; Exelon Earnings Top Estimates
markets.businessinsider.com - February 21 at 1:00 PM
Motus GI obtient un nouveau brevet pour les procédures endoscopiquesMotus GI obtient un nouveau brevet pour les procédures endoscopiques
fr.investing.com - February 21 at 1:00 PM
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI TractMotus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
finance.yahoo.com - February 21 at 1:00 PM
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI TractMotus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
globenewswire.com - February 21 at 8:52 AM
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of StockholdersMotus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
finance.yahoo.com - February 16 at 9:03 PM
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of StockholdersMotus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
globenewswire.com - February 16 at 4:15 PM
Motus GI Holdings Inc (MOTS)Motus GI Holdings Inc (MOTS)
investing.com - February 14 at 7:15 AM
Motus GI Holdings Inc MOTSMotus GI Holdings Inc MOTS
morningstar.com - February 8 at 11:15 AM
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel PreparationMotus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
finance.yahoo.com - January 30 at 2:11 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Apollo Endosurgery logo

Apollo Endosurgery

NASDAQ:APEN
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.
Arch Therapeutics logo

Arch Therapeutics

OTCMKTS:ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Isoray logo

Isoray

NYSE:ISR
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
Motus GI logo

Motus GI

NASDAQ:MOTS
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.